Disney disappointed Wall Street on Thursday with an earnings miss, but underlying figures show its streaming efforts are paying off.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
AI functions as a sidekick in healthcare labs, but it can make a huge difference by accelerating drug development and boosting data accuracy.
Target on Wednesday said its meal kit for four will cost less than $20 this year before tax, or about $5 a person.
The sportswear firm raised its full-year guidance for the third straight quarter on Wednesday and reported double-digit growth.
The US has basically imposed tariffs on Christmas this year: Trees, ornaments and even gifts. Now, both shoppers and sellers feel Grinchy.
AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.
The FAA said the flight cuts are pre-emptive to prevent safety issues as potentially more air traffic controllers call out.
For Musk to secure the full bag, Tesla must reach 20 million delivered EVs and a market cap of $8.5 trillion, up from $1.54 trillion today.
Microsoft wants to patent a system that thinks, acts and checks its results while handling patient data and working within hospital systems.
McDonald’s and other restaurants started rolling out value meals last year to keep orders coming despite economic pressures
Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer’s bid of $8 billion.
The deal, expected to close in the second half of 2026, comes as Kenvue’s Tylenol political fight is heating up.
Boston city council members are considering an ordinance that would require a “human safety operator” to be present in autonomous vehicles.
Major US airlines are already quietly cutting routes in the first quarter of 2026, experts told The Daily Upside.
Execs said that inflation-addled consumers are under the impression that Chipotle costs more than it does.
Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.